Drug Profile


Alternative Names: GM1; Sygen

Latest Information Update: 16 Jan 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fidia Farmaceutici
  • Class Gangliosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Spinal cord injuries; Stroke

Most Recent Events

  • 16 Jan 2001 Data have been added to the Parkinson's Disease and Movement Disorders therapeutic trials and adverse events sections
  • 08 Jan 2001 Discontinued-Clinical for Parkinson's disease in USA (SC)
  • 08 Jan 2001 Discontinued-Clinical for Spinal cord injuries in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top